CEO: A range of suitors for EpiTherapeutics
A number of drug companies courted Denmark’s EpiTherapeutics, but several factors resulted in US-based Gilead Sciences walking away with the prize, says the biotech’s CEO, Martin Bonde.
BY LONNI LYNGE
Although the initial papers were signed back in April, it was not until last week that a deal between Denmark’s EpiTherapeutics and US drug giant Gilead Sciences was finalized, CEO Martin Bonde told MedWatch immediately following the announcement of the USD 65 million deal.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Gilead Sciences buys Danish biotech company
For abonnenter
EpiTherapeutics approaches the clinic
For abonnenter
New normal for the founding of biotech companies
For abonnenter
